Novo Nordisk

Ask Sterling

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Favorites

Revenue Breakdown

Revenue Flow

Balance Sheet

Q3 2016-Q2 2026

Cash Flow

Q3 2016-Q2 2026

Novo Nordisk

Danish pharma; GLP-1 originator (Ozempic 2017, Wegovy 2021). CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Diabetes care leader; Novo Holdings acquired Catalent in 2024 to expand fill-finish capacity.

$NVOBagsværd, Denmark64,300novonordisk.com

SectorsGLP-1

Frequently asked questions

What does Novo Nordisk do?

Novo Nordisk (NVO) is a Drug Manufacturers - General company. Danish pharma; GLP-1 originator (Ozempic 2017, Wegovy 2021). CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Diabetes care leader; Novo Holdings acquired Catalent in 2024 to expand fill-finish capacity. It was founded in 1923, is headquartered in Bagsværd, Denmark and employs about 64,300 people.

How has Novo Nordisk's revenue and profitability trended?

Track Novo Nordisk's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 23, 2026.

Who are Novo Nordisk's main competitors?

Sterling groups Novo Nordisk in the GLP-1 sector, alongside Eli Lilly (LLY), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY), AstraZeneca (AZN) and Viking Therapeutics (VKTX).

If I'm investing in Novo Nordisk, what similar companies should I consider?

If you are researching Novo Nordisk, also look at Eli Lilly (LLY), Pfizer (PFE) and Amgen (AMGN). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.